Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Gradishar

Showing results (11-20 of 74) with videos related to

Pageof 8
Sort By:
Journal of Surgical Oncology|November 22, 2023
Treatment of residual disease following neoadjuvant therapy in breast cancerNatalie K Heater, Khyati Somayaji, William Gradishar
JAMA Oncology|January 30, 2016
Oncologists' Role in Patient Fertility Care: A Call to ActionTeresa K Woodruff, Kristin Smith, William Gradishar
The Oncologist|August 31, 2017
In ReplyWilliam Gradishar, Krystal Brown, Erin Mundt, et al.
Clinical Breast Cancer|May 6, 2023
Risk of Recurrence in Patients With HER2+ Early-Stage Breast Cancer: Literature Analysis of Patient and Disease CharacteristicsJoyce O'Shaughnessy, William Gradishar, Ruth O'Regan, et al.
Breast (Edinburgh, Scotland)|August 17, 2011
Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysisMatti Aapro, Sergei Tjulandin, Paul Bhar, et al.
Nature Reviews. Drug Discovery|March 2, 2011
Eribulin mesylateTimothy K Huyck, William Gradishar, Fil Manuguid, et al.
Current Treatment Options in Oncology|February 12, 2019
Innovating Cancer Care Delivery: the Example of the 4R Oncology Model for Colorectal Cancer PatientsJulia Trosman, Christine Weldon, Sheetal Kircher, et al.
The Oncologist|April 15, 2017
Clinical Variant Classification: A Comparison of Public Databases and a Commercial Testing LaboratoryWilliam Gradishar, KariAnne Johnson, Krystal Brown, et al.
Journal of the Peripheral Nervous System : JPNS|April 27, 2018
Risk factors for the development of paclitaxel-induced neuropathy in breast cancer patientsJetter Robertson, Jeffrey Raizer, James S Hodges, et al.
American Journal of Clinical Oncology|February 8, 2013
Markov model and cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancerTamer Refaat, Mehee Choi, Germaine Gaber, et al.
Pageof 8

Showing results (11-20 of 74) with videos related to

Sort By:
Pageof 8
Journal of Surgical Oncology|November 22, 2023
Treatment of residual disease following neoadjuvant therapy in breast cancerNatalie K Heater, Khyati Somayaji, William Gradishar
JAMA Oncology|January 30, 2016
Oncologists' Role in Patient Fertility Care: A Call to ActionTeresa K Woodruff, Kristin Smith, William Gradishar
The Oncologist|August 31, 2017
In ReplyWilliam Gradishar, Krystal Brown, Erin Mundt, et al.
Clinical Breast Cancer|May 6, 2023
Risk of Recurrence in Patients With HER2+ Early-Stage Breast Cancer: Literature Analysis of Patient and Disease CharacteristicsJoyce O'Shaughnessy, William Gradishar, Ruth O'Regan, et al.
Breast (Edinburgh, Scotland)|August 17, 2011
Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysisMatti Aapro, Sergei Tjulandin, Paul Bhar, et al.
Nature Reviews. Drug Discovery|March 2, 2011
Eribulin mesylateTimothy K Huyck, William Gradishar, Fil Manuguid, et al.
Current Treatment Options in Oncology|February 12, 2019
Innovating Cancer Care Delivery: the Example of the 4R Oncology Model for Colorectal Cancer PatientsJulia Trosman, Christine Weldon, Sheetal Kircher, et al.
The Oncologist|April 15, 2017
Clinical Variant Classification: A Comparison of Public Databases and a Commercial Testing LaboratoryWilliam Gradishar, KariAnne Johnson, Krystal Brown, et al.
Journal of the Peripheral Nervous System : JPNS|April 27, 2018
Risk factors for the development of paclitaxel-induced neuropathy in breast cancer patientsJetter Robertson, Jeffrey Raizer, James S Hodges, et al.
American Journal of Clinical Oncology|February 8, 2013
Markov model and cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancerTamer Refaat, Mehee Choi, Germaine Gaber, et al.
Pageof 8